Therapeutic Effect and Mechanism of Yiqi Huoxue Tongbian Prescription on Slow Transit Constipation in Rats
10.13422/j.cnki.syfjx.20231318
- VernacularTitle:益气活血通便方对慢传输型便秘大鼠的治疗作用及机制
- Author:
Shuo LI
1
;
Xiaoling YANG
1
;
Shubin LIU
2
;
Benhuan WANG
1
;
Guisen ZHENG
1
;
Guojian DUAN
1
;
Linhua ZHAO
3
;
Xiujuan YANG
1
;
Xiaolin TONG
3
Author Information
1. Gansu University of Chinese Medicine， Lanzhou 730000， China
2. Gansu Provincial Hospital of TCM， Lanzhou 730050， China
3. Guang'anmen Hospital， China Academy of Chinese Medical Sciences， Beijing 100053， China
- Publication Type:Journal Article
- Keywords:
slow transit constipation;
Yiqi Huoxue Tongbian prescription;
aquaporin;
neurotransmitters;
intestinal flora
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2023;29(23):16-27
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo explore the therapeutic effect and mechanism of Yiqi Huoxue Tongbian prescription on slow transit constipation （STC） in rats. MethodThe rat model of STC was established by gavage of loperamide hydrochloride. Rats were assigned into control， model， mosapride， low-， medium-， and high-dose （3.51， 7.02， and 14.04 g·kg-1， respectively） Yiqi Huoxue Tongbian prescription groups. The changes of general signs， fecal moisture content， and intestinal propulsion rate were measured after model establishment and drug administration. The colonic mucosal changes were observed by hematoxylin eosin staining. Enzyme-linked immunosorbent assay was employed to determine the content of substance P （SP） and vasoactive intestinal peptide （VIP） in the colon of rats in each group. The gray values of aquaporin （AQP） 3， AQP4， AQP8， and c-Kit in rat colon tissue were measured by immunohistochemistry and Western blot， and the changes of intestinal flora were detected by 16S rRNA high-throughput sequencing. ResultCompared with the model group， 10 days of treatment with Yiqi Huoxue Tongbian prescription increased the fecal moisture content and intestinal propulsion rate （P<0.01）. The medium- and high-dose Yiqi Huoxue Tongbian prescription groups and the mosapride group showed no obvious mucosal inflammation and neat arrangement of goblet cells with a large number in the colon tissue. Moreover， the three groups showed increased SP content （P<0.01） and decreased VIP content （P<0.01） in the serum. The medium- and high-dose Yiqi Huoxue Tongbian prescription groups showed down-regulated protein levels of AQP3， AQP4， and AQP8 （P<0.01） and up-regulated protein level of c-Kit （P<0.01）. The drug administration groups presented slightly increased observed species， Chao1， ACE， and Shannon， Simpson， and PD whole tree. The principal component analysis showed that the control group had a short distance with the high- and medium-dose Yiqi Huoxue Tongbian prescription groups， indicating that high- and medium-dose Yiqi Huoxue Tongbian prescription can recover the intestinal flora to that in the control group. ConclusionYiqi Huoxue Tongbian prescription can alleviate the defecation status of rats with slow transit constipation by down-regulating the expression of AQP3， AQP4， and AQP8 to reduce the absorption of water in the intestine， up-regulating the expression of c-Kit to increase the number and distribution of Cajal interstitial cells， and regulating the balance of flora in the colon tissue.
